NCT05048212View on ClinicalTrials.gov

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Brain MetastasesRenal Cell Carcinoma
Interventions
DRUG

Nivolumab

Given by IV

DRUG

Ipilimumab

Given by IV

DRUG

Cabozantinib

Given by IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER